New Dimensions in Target Organ Protection Comprehensive Cardiovascular Protection

Chicago, IL

Select Session

click below to choose a session for viewing
for webcast help click here

The Current Landscape of Comprehensive Cardiovascular Risk Management and Target Organ Protection – Addressing the Complexities of the Comorbidity Continuum: Hypertension, CHD and Diabetes
Program Chairman: Matthew R. Weir, MD

Mechanisms of End Organ Damage and the Vascular Biology of Hypertension – A Look Behind the Curtain and Beyond the Numbers: Mechanisms and Injury and Implications for Treatment
Ernesto L. Schiffrin, MD, PhD, FRSC, FRCPC, FACP

A Winning Combination – Applying Hypertension Treatment to Vascular Outcomes and Target Organ Protection: Evidence-Based Approaches Focusing on Fixed Combination Therapy and Compelling Conditions in the Setting of Heart Disease
Kenneth A. Jamerson, MD

The Foundation Role of ARBs, Direct Renin Inhibitors (DRIs) and ACE Inhibitors for Vascular End Point Salvage: Focus on Diabetes, Ischemic Heart Disease and Renal Protection
Matthew R. Weir, MD

Inhibiting the Renin Angiotensin System (RAS) – Lessons from Clinical Trials: Focus on Heart Failure and Adverse Cardiovascular Outcomes
Marc Pfeffer, MD

Case Studies in Comprehensive Cardiovascular Protection – Question and Answer Interactive Session
Faculty Panel